Minerva Surgical

Minerva Surgical, Inc. is a medical technology company, which engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. It offers therapeutic devices for abnormal uterine bleeding treatment. The company was founded by Csaba Truckai in 2008 and is headquartered in Santa Clara, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. It offers therapeutic devices for abnormal uterine bleeding treatment. The company was founded by Csaba Truckai in 2008 and is headquartered in Santa Clara, CA.

Minerva Surgical (NASDAQ: UTRS ) stock is taking a beating on Monday after the women's healthcare company announced that its shares will be delisted later this month. According to a filing with the Securities and Exchange Commission (SEC), the company's shares will no longer trade on the Nasdaq Exchange starting on Dec. 29.

Why Is Minerva Surgical (UTRS) Stock Down 50% Today?

SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023.

Minerva Surgical Reports Third Quarter 2023 Financial Results

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Caroline Corner - IR Todd Usen - President & CEO Joel Jung - CFO Conference Call Participants Operator Greetings, and welcome to the Minerva Surgical Q2 2023 Earnings Call. At this time all participants are in listen-only mode.

Minerva Surgical, Inc. (UTRS) Q2 2023 Earnings Call Transcript

Minerva Surgical, Inc. (UTRS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.20 per share a year ago.

Minerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates

SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023.

Minerva Surgical Reports Second Quarter 2023 Financial Results

Ameri Holdings

Unique Fabricating

Investing in newly public penny stocks is a dynamic and potentially rewarding avenue to expand one's portfolio. This niche market represents an opportunity for forward-thinking investors willing to navigate the financial landscape with patience, research, and calculated risk-taking.

How to Handle IPOs With Penny Stocks, 3 Tips

Altamira Therapeutics Ltd

Getaround Inc

If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.

Best Penny Stocks Today? 3 Under $1 To Watch Now

Minerva Surgical (NASDAQ: UTRS ) stock is rising higher on Wednesday despite a lack of news from the surgical and medical instrument manufacturing company. There have been no new press releases or filings with the Securities and Exchange Commission (SEC) that would explain why shares of UTRS stock are rising today.

Why Is Minerva Surgical (UTRS) Stock Up 229% Today?

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Caroline Corner - Investor Relations Todd Usen - President & CEO, Director Joel Jung - Chief Financial Officer Conference Call Participants Phillip Dantoin - Piper Sandler Operator Good day and thank you for standing by. Welcome to Minerva Surgical First Quarter 2023 Earnings Conference Call.

Minerva Surgical, Inc. (UTRS) Q1 2023 Earnings Call Transcript

SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023.

Minerva Surgical Reports First Quarter 2023 Financial Results

SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce First Quarter 2023 Financial Results

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Caroline Corner - IR Todd Usen - President and CEO Joel Jung - CFO Conference Call Participants Operator Thank you for standing by, and welcome to Minerva's Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Minerva Surgical, Inc. (UTRS) Q4 2022 Earnings Call Transcript

SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions.

Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported fourth quarter and full-year financial results for the period ended December 31, 2022.

Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results

SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results

SANTA CLARA, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has closed on the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed Partners (Accelmed), with participation by New Enterprise Associates, at an offering price of $0.2046 per share. Accelmed is now the controlling stockholder of Minerva Surgical.

Minerva Surgical Closes $30 Million Private Placement of Common Stock

SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time.

Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference

SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment and has entered into a consulting agreement for 12 months following his retirement.

Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical.

Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners

SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY.

Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference

Minerva Surgical, Inc. (NASDAQ:UTRS ) Q3 2021 Earning Conference Call November 14, 2022 4:30 PM ET Company Representatives Dave Clapper - President, Chief Executive Officer Joel Jung - Chief Financial Officer Caroline Corner - Investor Relations Conference Call Participants Rohan Raheja - J.P. Morgan Matt O'Brien - Piper Sandler Operator Good day, and welcome to Minerva's Third Quarter 2022 Earnings Call.

Minerva Surgical, Inc. (UTRS) Q3 2022 Earnings Call Transcript

SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022.

Minerva Surgical Reports Third Quarter 2022 Financial Results

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call. It will now report its third quarter 2022 financial results on Monday, November 14, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call

SANTA CLARA, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Minerva Surgical to Announce Third Quarter 2022 Financial Results

SANTA CLARA, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 a.m. Eastern Time on Monday, September 12, 2022.

News for Minerva Surgical Stock (UTRS)